分享产品介绍 评论(0)
分子别名
Povetacicept, ALPN-303表达宿主
HEK293分子量
55-60kDa (Non-Reducing)纯度
＞95% by SDS-PAGE活性
1. Protein A Chip captured Povetacicept (Cat. No. UA016160), can bind BAFF/TNFSF13B/CD257 Trimer His Tag Protein, Human (Cat. No. UA016073) with an affinity constant of 82.34pM as determined in SPR assay. 2. Protein A Chip captured Povetacicept (Cat. No. UA016160), can bind BAFF&APRIL Heterotrimer His Tag Protein, Human (Cat. No. UA011338) with an affinity constant of 0.12nM as determined in SPR assay.标记
Unconjugated性状
Lyophilized Powder缓冲体系
PBS, pH7.4, 5% trehalose
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
文献引用
1.Stacey Dillon, et al. Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice. Front. Immunol., 06 June 2025.
2.Evans LS, et al. Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases. Arthritis Rheumatol. 2023;75(7):1187-1202.
Povetacicept (ALPN-303) is an engineered Fc fusion protein consisting of a variant domain of human TACI receptor (containing key amino acid substitutions) fused to an effector-less human IgG1 Fc fragment, functioning as a dimer to exert high-affinity dual antagonistic activity. Its mechanism of action is achieved through simultaneous binding and inhibition of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL)—the former regulates early B-cell development and activates T cells, while the latter supports plasma cell survival, both collectively driving pathogenic B-cell and autoantibody production. Clinical studies (RUBY-3) have demonstrated that this agent reduces proteinuria by 64% and galactose-deficient IgA1 by 77% in IgA nephropathy, with approximately 90% of patients achieving resolution of hematuria; in membranous nephropathy, anti-PLA2R antibodies decreased by 83%, with 100% reaching immunological remission, and the safety profile has been favorable. Currently, a Phase III confirmatory study (RAINIER) has been initiated in IgA nephropathy, and the drug has also shown therapeutic potential in other autoantibody-associated diseases such as myasthenia gravis.
电泳
2μg (R: reducing condition, N:non-reducing condition).
体积排阻色谱(SEC-HPLC)
The purity of Povetacicept is more than 95% as determined by SEC-HPLC.
SPR
Protein A Chip captured Povetacicept (Cat. No. UA016160), can bind BAFF/TNFSF13B/CD257 Trimer His Tag Protein, Human (Cat. No. UA016073) with an affinity constant of 82.34pM as determined in SPR assay.
Protein A Chip captured Povetacicept (Cat. No. UA016160), can bind BAFF&APRIL Heterotrimer His Tag Protein, Human (Cat. No. UA011338) with an affinity constant of 0.12nM as determined in SPR assay.
评论(0)